We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Millions of 3D-Printed Nasopharyngeal Swabs for COVID-19 Testing to Reach Healthcare Providers

By LabMedica International staff writers
Posted on 28 Apr 2020
Print article
Image: Origin swabs (Photo courtesy of Origin)
Image: Origin swabs (Photo courtesy of Origin)
In response to the severe shortage of testing supplies for widespread COVID-19 testing of millions of people, millions of 3D-printed nasal swabs are expected to soon reach health workers.

Stratasys, Inc. (Eden Prairie, MN, USA) and Origin (San Francisco, CA, USA) have signed an agreement in which Stratasys will market and promote Origin 3D-printed nasopharyngeal (NP) swabs to healthcare providers and other testing centers in the US.

Widespread testing of millions of people is currently hampered by a shortage of testing supplies. Each Origin One 3D printer has the ability to produce batches of 1,500 Origin NP O1 Swabs at a time, multiple times daily. Origin is moving towards a streamlined process allowing the production of approximately 190,000 per day, or 1.3 million per week. Stratasys will leverage its position as a provider of 3D printing solutions to the healthcare industry to market Origin NP O1 Swabs.

Origin swabs were tested in a clinical trial with Beth Israel Deaconess Medical Center, an academic medical center affiliated with Harvard Medical School, and performed the highest with regard to concordance to control swabs compared to two other 3D printed swabs. Each Origin NP O1 Swab is autoclavable and individually packaged.

Stratasys Americas President Rich Garrity said Stratasys is ready to help get millions of swabs to wherever they are most needed. “We have tremendous confidence in Origin’s 3D printing technology, and we’re confident in our ability to help bring them to market efficiently,” he said.

Origin CEO, Christopher Prucha said Origin is ready to scale quickly. “We believe widespread testing can help save lives and get our economy going again, and we’re confident that our Origin One technology and simple material requirements will be able to produce millions of swabs to meet the need,” he said. “We’ve been impressed by the speed with which Stratasys has been able to provide thousands of shields to healthcare systems across the country and believe they are the right partner for helping get millions of swabs where they are most needed.”

Related Links:
Stratasys, Inc.
Origin


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
cTnI/CK-MB/Myo Test
Finecare cTnI/CK-MB/Myo Rapid Quantitative Test
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.